NVS

Novartis AG ADR

NVS, USA

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.

https://www.novartis.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
NVS
stock
NVS

Novartis AG $NVS is Parkwood LLC's 6th Largest Position MarketBeat

Read more →
NVS
stock
NVS

Novartis (NVS) Enters $1.7 Billion Development Deal, Says Report Yahoo Finance

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

HOLD

Target Price:

$132.7711

Analyst Picks

Strong Buy

0

Buy

2

Hold

9

Sell

0

Strong Sell

2

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Earnings Ratio (P/E)

-

Very High

17.64

Low ≥ 50

High ≤ 10

Price to Book Ratio (P/B)

-

Very High

5.80

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

8.86 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Low

3.66 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very High

39.98 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very Low

1.41

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 6.21% of the total shares of Novartis AG ADR

1.

Dodge & Cox

(0.55%)

since

2025/06/30

2.

PRIMECAP Management Company

(0.5373%)

since

2025/06/30

3.

Dimensional Fund Advisors, Inc.

(0.4681%)

since

2025/06/30

4.

Dodge & Cox Stock I

(0.4206%)

since

2025/06/30

5.

Morgan Stanley - Brokerage Accounts

(0.3905%)

since

2025/06/30

6.

Vanguard PRIMECAP Inv

(0.3806%)

since

2025/06/30

7.

Fisher Asset Management, LLC

(0.3679%)

since

2025/06/30

8.

Loomis, Sayles & Company LP

(0.2883%)

since

2025/06/30

9.

Bank of America Corp

(0.2339%)

since

2025/06/30

10.

Franklin Resources Inc

(0.219%)

since

2025/06/30

11.

Goldman Sachs Group Inc

(0.1313%)

since

2025/06/30

12.

Wellington Management Company LLP

(0.1293%)

since

2025/06/30

13.

DFA International Core Equity 2 I

(0.1265%)

since

2025/07/31

14.

BlackRock Inc

(0.1199%)

since

2025/06/30

15.

Renaissance Technologies Corp

(0.1187%)

since

2025/06/30

16.

Principal Financial Group Inc

(0.1184%)

since

2025/06/30

17.

Northern Trust Corp

(0.1138%)

since

2025/06/30

18.

HHG PLC

(0.1126%)

since

2025/06/30

19.

Cullen Capital Management, LLC

(0.1089%)

since

2025/03/31

20.

Wells Fargo & Co

(0.0963%)

since

2025/06/30

21.

Envestnet Asset Management Inc

(0.0897%)

since

2025/06/30

22.

Franklin Mutual Global Discovery Z

(0.0869%)

since

2025/07/31

23.

State Street Corp

(0.0825%)

since

2025/06/30

24.

FMR Inc

(0.0796%)

since

2025/06/30

25.

Loomis Sayles Growth Y

(0.0786%)

since

2025/07/31

26.

Vanguard Capital Opportunity Inv

(0.0741%)

since

2025/06/30

27.

Russell Investments Core Equity SMA

(0.0732%)

since

2025/06/30

28.

Principal Equity Income A

(0.0729%)

since

2025/07/31

29.

Hartford Dividend and Growth Y

(0.065%)

since

2025/07/31

30.

Franklin Mutual Shares Z

(0.0535%)

since

2025/07/31

31.

Dimensional International Value ETF

(0.0498%)

since

2025/08/29

32.

Janus Henderson Global Life Sciences D

(0.0495%)

since

2025/06/30

33.

Janus Henderson Global Life Sciences

(0.0495%)

since

2025/06/30

34.

Vanguard PRIMECAP Core Inv

(0.0449%)

since

2025/06/30

35.

Franklin Mutual Beacon Z

(0.0426%)

since

2025/07/31

36.

Janus Global Life Science AUSD

(0.0409%)

since

2025/06/30

37.

Janus Henderson Glb Life Scn I2 USD

(0.0396%)

since

2025/08/31

38.

Dimensional International Core Eq 2 ETF

(0.0357%)

since

2025/08/29

39.

Dimensional International Cr Eq Mkt ETF

(0.0334%)

since

2025/08/29

40.

Loomis Sayles US Growth Eq I/A USD

(0.0322%)

since

2025/07/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

1.93

Latest Release

Date

2025-09-30

EPS Actual

2.25

EPS Estimate

2.31

EPS Difference

-0.06

Surprise Percent

-2.5974%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(4)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(3)
Economic Moat
Wide Moat Company(7.8)
GARP
Not Attractive for GARP(3)
Growth
Weak Growth Prospect(3)
Momentum
Moderate Momentum(4)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
High Quality(7.5)
Value
Fair Value(5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.